Carcinogenesis Advance Access originally published online on September 29, 2005
Carcinogenesis 2006 27(3):551-559; doi:10.1093/carcin/bgi231
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Carcinogenesis vol.27 no.3 © Oxford University Press 2005; all rights reserved.
Growth inhibition of carcinogen-transformed MCF-12F breast epithelial cells and hormone-sensitive BT-474 breast cancer cells by 1
-hydroxyvitamin D5
1 Department of Surgical Oncology and 2 Department of Human Nutrition, University of Illinois at Chicago, Chicago, IL 60612 and 3 IIT Research Institute, Chicago, IL 60616, USA
* To whom correspondence should be addressed. IIT Research, Institute, 10 West 35th Street, Chicago, IL 60616, USA. Email: RMehta{at}iitri.org
Several studies have established the active form of vitamin D3 as an effective tumor-suppressing agent; however, its antitumor activity is achieved at doses that are hypercalcemic in vivo. Therefore, less calcemic vitamin D3 analog, 1
-hydroxy-24-ethyl-cholecalciferol (1[OH]D5), was evaluated for its potential use in breast cancer chemoprevention. Previously, 1(OH)D5 showed anticarcinogenic activity in several in vivo and in vitro models. However, its effects on growth of normal tissue were not known. The present study was conducted to determine the effects of 1(OH)D5 on the growth of normal mouse mammary gland and normal-like human breast epithelial MCF-12F cells and to compare these effects with carcinogen-transformed MCF-12F and breast cancer cells. No significant difference was observed in the growth or morphology of cultured mouse mammary gland and MCF-12F cells in the presence of 1(OH)D5. However, the transformed MCF-12F cells underwent growth inhibition (40–60%, P < 0.05) upon 1(OH)D5 treatment as determined by cell viability assays. Cell cycle analysis showed marked increase (50%) in G-1 phase for cells treated with 1(OH)D5 compared with the controls. Moreover, the percentage of cells in the synthesis (S) phase of cell cycle was decreased by 70% in transformed MCF-12F, BT-474 and MCF-7 cells. The growth arrest was preceded by an increase in expression of cell cycle regulatory proteins p21Waf-1 and p27Kip-1. In addition, differential expression studies of parent and transformed MCF-12F cell lines using microarrays showed that prohibitin mRNA was increased 4-fold in the transformed cells. These results indicate that the growth inhibitory effect of 1(OH)D5 was achieved in both carcinogen-transformed MCF-12F and breast cancer cells at a dose that was non-inhibitory in normal-like breast epithelial cells.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  X. Peng, P. Jhaveri, E. A. Hussain-Hakimjee, and R. G. Mehta Overexpression of ER and VDR is not sufficient to make ER-negative MDA-MB231 breast cancer cells responsive to 1{alpha}-hydroxyvitamin D5 Carcinogenesis, May 1, 2007; 28(5): 1000 - 1007. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-Z. Feng, T. Shiozawa, T. Miyamoto, H. Kashima, M. Kurai, A. Suzuki, J. Ying-Song, and I. Konishi Overexpression of Hedgehog Signaling Molecules and Its Involvement in the Proliferation of Endometrial Carcinoma Cells Clin. Cancer Res., March 1, 2007; 13(5): 1389 - 1398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Peng, R. Mehta, S. Wang, S. Chellappan, and R. G. Mehta Prohibitin is a novel target gene of vitamin d involved in its antiproliferative action in breast cancer cells. Cancer Res., July 15, 2006; 66(14): 7361 - 7369. [Abstract] [Full Text] [PDF]
|
|